Vor Bio Announces Research On Barriers To Cell And Gene Therapy Clinical Trial Enrollment, Citing Complexity, Logistical Challenges, And Resource Constraints; Findings Presented At TANDEM Meetings Highlight Need For Improved Patient Experience.

-8.26%

Vor Biopharma, Inc.

VOR

0.00

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials
Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options

CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials. The data, which was presented at the TANDEM Meetings of ASTCT and CIBMTR, demonstrated the need to improve the process and experience of patients considering and enrolling in CGT trials.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Is Rising Institutional Interest and Analyst Coverage Shaping Immunocore’s Trajectory (IMCR)?

Molecular Partners Demonstrates Tumor-Localized Immune Activation With Logic-Gated CD3 Switch-DARPin Inducing Significant Tumor Regression Without Systemic Cytokine Release

Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket

Will FDA Approval of Revuforj for AML Transform Syndax Pharmaceuticals' (SNDX) Investment Narrative?

We're Keeping An Eye On Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Rate

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vertex Pharmaceuticals Raises FY2025 Sales Guidance from $11.850B-$12.000B to $11.900B-$12.000B vs $11.987B Est

Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket